Sangamo Therapeutics, Inc. - SGMO STOCK NEWS

Sangamo Therapeutics (Nasdaq: SGMO) received FDA clearance for its IND application for ST-503, an epigenetic regulator targeting chronic neuropathic pain in idiopathic small fiber neuropathy (iSFN). The company plans to initiate a Phase 1/2 study in mid-2025 to evaluate this one-time intrathecal treatment. ST-503 uses AAV vector technology with zinc finger repressors to target the SCN9A gene, which controls Nav1.7 sodium channels important for pain signaling. The treatment addresses iSFN, affecting an estimated 43,000 U.S. patients, with broader peripheral neuropathies impacting nearly 40 million Americans. Preclinical research showed promising results in reducing pain hypersensitivity with no off-target effects.

Sangamo Therapeutics reported significant Q3 2024 developments, including FDA's agreement for Accelerated Approval pathway for its Fabry disease gene therapy, potentially advancing approval by three years. The company received $50 million in upfront fees from Genentech, with potential for $1.9 billion in additional milestone payments. Q3 financial results showed net income of $10.7 million ($0.04 per share), with revenues of $49.4 million. Cash position stands at $39.2 million, expected to fund operations into Q1 2025. Pfizer will present Phase 3 AFFINE trial data for Hemophilia A gene therapy at ASH, showing positive results in meeting primary endpoints.

Sangamo Therapeutics (Nasdaq: SGMO) has announced it will release its third quarter 2024 financial results after market close on Tuesday, November 12, 2024. The company will host a conference call at 4:30 p.m. Eastern on the same day to discuss financial results and provide business updates. Participants can register for the call through a provided link and are advised to join 10 minutes before the start. The webcast will be available on Sangamo's website in the Investors and Media section, with a replay accessible afterward.

Sangamo Therapeutics (SGMO) reported Q2 2024 results and recent business highlights:

Key developments:

• Announced global license agreement with Genentech for neurodegenerative disease therapies, potentially worth up to $1.9 billion plus royalties
• Reported positive Phase 3 results for Hemophilia A gene therapy developed with Pfizer
• Continued progress in Phase 1/2 Fabry disease gene therapy trial
• Advancing neurology-focused preclinical pipeline

Financial results:

• Q2 net loss: $36.1 million ($0.18 per share)
• Q2 revenue: $0.3 million
• Cash position: $27.8 million as of June 30, 2024
• Expects $50 million in near-term payments from Genentech deal

Sangamo believes its cash runway extends into Q1 2025 with the Genentech payments.

Sangamo Therapeutics (Nasdaq: SGMO) has entered a global license agreement with Genentech to develop intravenous genomic medicines for neurodegenerative diseases. The deal focuses on Sangamo's zinc finger repressors targeting the tau gene, important in Alzheimer's and tauopathies, and another undisclosed neurology target. Sangamo is also licensing its proprietary AAV capsid, STAC-BBB, which has shown strong blood-brain barrier penetration.

Key financial terms include:

• $50 million in near-term upfront fees and milestone payments
• Up to $1.9 billion in potential development and commercial milestones
• Tiered royalties on net sales

Sangamo will handle technology transfer and preclinical activities, while Genentech will lead clinical development, regulatory interactions, manufacturing, and global commercialization.

Sangamo Therapeutics (Nasdaq: SGMO), a genomic medicine company, has scheduled its second quarter 2024 financial results release for Tuesday, August 6, 2024, after market close. The company will host a conference call at 4:30 p.m. Eastern on the same day to review the results and provide business updates.

Participants can register and access the call using a provided link, with a recommendation to join 10 minutes early. The call will offer options to dial in or use a dial-out feature for instant phone connection. A live webcast will be available on the Sangamo website's Investors and Media section, with a replay accessible afterwards under Events.

Sangamo Therapeutics (SGMO) reported on Pfizer's announcement of positive topline results from the Phase 3 AFFINE trial evaluating giroctocogene fitelparvovec, a gene therapy for hemophilia A. The trial met its primary objective of non-inferiority and superiority in total annualized bleeding rate (ABR) compared to routine Factor VIII replacement. Key findings include:

- Significant ABR reduction (1.24 vs 4.73)
- 84% of participants maintained FVIII activity >5% at 15 months
- 98.3% reduction in mean treated ABR
- Generally well-tolerated safety profile

Sangamo is eligible for up to $220 million in milestone payments and 14-20% royalties if approved. The therapy aims to provide long-term bleed protection with a single infusion.

In the PR, Sangamo Therapeutics reported recent business highlights, including raising $24 million in gross proceeds, progress in neurology pipeline, completion of dosing in Phase 1/2 STAAR study for Fabry disease, and ongoing discussions with potential Fabry collaboration partners. Pfizer anticipates BLA and MAA submissions for Hemophilia A collaboration in early 2025. Financially, Sangamo reported a net loss of $49.1 million in Q1 2024 compared to a net income of $21.1 million in Q1 2023, with revenues decreasing to $0.5 million from $158.0 million in the same period in 2023. The non-GAAP total operating expenses decreased to $43.6 million in Q1 2024 from $69.5 million in Q1 2023. Cash and cash equivalents were $54.4 million as of March 31, 2024.

Sangamo Therapeutics, Inc. presented pre-clinical data on their innovative Modular Integrase (MINT) technology, aimed at large-scale genome editing. The MINT platform utilizes Bxb1 to integrate large DNA sequences into the genome with potential applications in treating patients with unique mutations. The technology is designed to simplify manufacturing, reduce translocation risk, and enable targeted integration without the need for additional genome editing tools. The company views the MINT platform as a valuable tool for neurology-focused indications and potential collaborations in human disease and agricultural biotech.